Transcenta Group will announce the latest business progress of the TST003 project, the first antibody of its kind, at the 10th TEMTIA meeting

Transcenta Group (06628.
HK), a clinical-stage biopharmaceutical company with the ability to integrate the whole process of biopharmaceutical discovery, R&D, process development and manufacturing, announced on October 24 that it has been invited to attend the 10th TEMTIA (International Association of EMT) conference in Paris, France, November 7-10, and to announce the preclinical data
of TST003.
TST003 is Transcenta's first-of-its-kind high-affinity humanized monoclonal antibody
targeting Gremlin1.

Presentation Details:

: TST003, a first-of-its-kind anti-Gremlin1 monoclonal antibody, can block epithelial mesenchymal transformation, showing promising antitumor activity of a single agent against a variety of refractory solid tumors

Date & Time: 9 November 2022, 3:30pm-3:45pm (Paris time)

Speaker: Dr.
Xueming Qian, CEO of Transcenta Group

TEMTIA is an international conference
dedicated to the study of epithelial mesenchymal transformation (EMT).
The EMT process is triggered when epithelial cells lose their adhesion, epithelial cell features are gradually lost, and an individualized motor phenotype is adopted
.
EMT was originally defined as a developmental stage and contributes to the progression and metastasis of
cancer.
EMT has been shown to be an important mechanism
of resistance in tumor treatments, including checkpoint inhibitor immunotherapy.

About TST003

TST003 is a high-affinity monoclonal antibody that targets Gremlin1
, a member of the TGF-β superfamily.
Gremlin1 protein is a highly conserved secreted protein that plays an important role
in development.
Gremlin1 is highly upregulated
in a variety of solid tumors.
Gremlin1 protein promotes epithelial-mesenchymal conversion
.
TST003 demonstrated promising single-agent activity
in a variety of refractory solid tumors resistant to checkpoint inhibitors, including castration-resistant prostate cancer and microsatellite stable metastatic colorectal cancer.
In homologous transplanted mouse models, TST003 also enhances the antitumor activity
of checkpoint inhibitors.
TST003 was approved by the FDA for clinical trials
in September 2022.